Autoimmune disease risk may differ by menopausal hormone therapy formulation
Progestogen, when used in hormone therapy, is recognized for its benefits in protecting the uterus. A new study suggests that its addition limits the increased risk of composite autoimmune disease associated with estrogen-only therapy. Results of the study were presented at the 2026 Annual Meeting of The Menopause Society in San Diego, Oct. 20–24, 2026.
Read original article on Medical Xpress - latest medical and health news stories →Related news
-
Combined estrogen and testosterone therapy increases lumbar spine bone mineral density
United Kingdom
-
Premature menopause associated with higher insulin levels and greater CVD risk
United Kingdom
-
Higher physical activity frequency associated with lower symptom burden in perimenopause
United Kingdom
-
Protecting young skin: A new approach to melanoma prevention for children
United Kingdom
-
Building social and emotional skills in preschool improved life for young adults
United Kingdom
-
Scientists discover immune pathway behind radiation-induced lung damage
United Kingdom
-
Machine learning can identify older heart failure patients at risk of losing independence
United Kingdom
-
Machine learning spots hidden risk of functional decline after heart failure
United Kingdom